<DOC>
	<DOCNO>NCT02912845</DOCNO>
	<brief_summary>The primary purpose study confirm safety KamRAB ( Human Rabies Immunoglobulin ) child age 0 month &lt; 17 year , administer part post-Rabies Exposure Prophylaxis ( PEP ) .</brief_summary>
	<brief_title>Post-marketing Study KamRAB Administered Single Dose With Active Rabies Vaccine Children Exposed Rabies</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<criteria>Healthy child ( male female ) age 0 month &lt; 17 year . Have expose possibly exposed rabies . Are indicated receive postexposure prophylaxis ( PEP ) rabies infection . Have document informed consent child 's parent ( ) legal guardian ( ) assent child appropriate . History previous administration rabies vaccine human rabies immune globulin ( HRIG ) Rabies exposure possible rabies exposure seven day prior initiation PEP , time exposure unknown</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>